We are live on
!
Find out more
HA
HHLR Advisors Portfolio holdings
AUM
$1.67B
1-Year Est. Return
7.53%
This Fund
S&P 500
This Quarter
Est. Return
+5.43%
1 Year Est. Return
+7.53%
3 Year Est. Return
+82.23%
5 Year Est. Return
+55.28%
10 Year Est. Return
–
AUM
$9.71B
AUM Growth
-$405M
(-4%)
Cap. Flow
-$603M
Cap. Flow
% of AUM
-6.21%
Top 10 Holdings %
Top 10 Hldgs %
61.24%
Holding
100
New
9
Increased
6
Reduced
17
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Airbnb
ABNB
|
+$331M |
| 2 |
Vipshop
VIPS
|
+$213M |
| 3 |
MINISO
MNSO
|
+$128M |
| 4 |
Alibaba
BABA
|
+$128M |
| 5 |
DIDI
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
|
+$42.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pinduoduo
PDD
|
+$432M |
| 2 |
CBPO
China Biologic Products Holdings, Inc.
CBPO
|
+$351M |
| 3 |
Zoom
ZM
|
+$316M |
| 4 |
GDS Holdings
GDS
|
+$214M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.46% |
| 2 | Consumer Discretionary | 24.31% |
| 3 | Technology | 11.89% |
| 4 | Communication Services | 10.14% |
| 5 | Financials | 5.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Dyne Therapeutics
DYN
$4.12B
| $21M | 0.22% |
1,000,000
| – | – |
|
52
Allogene Therapeutics
ALLO
$594M
| $20.9M | 0.21% |
800,000
| – | – |
|
53
Keurig Dr Pepper
KDP
$42.4B
| $20.1M | 0.21% |
569,584
-390,570
| -41% | -$13.9M |
|
54
Century Therapeutics
IPSC
$364M
| $18M | 0.19% |
+614,095
| New | +$15.6M |
|
55
Regenxbio
RGNX
$613M
| $17.7M | 0.18% |
456,000
| – | – |
|
56
Olema Pharmaceuticals
OLMA
$984M
| $17.4M | 0.18% |
620,397
| – | – |
|
|
MOGU
57
MOGU Inc
MOGU
$17.3M
| $17.3M | 0.18% |
870,581
| – | – |
|
|
BEDU
58
DELISTED
Bright Scholar Education Holdings
BEDU
| $16.9M | 0.17% |
996,449
| – | – |
|
59
Prelude Therapeutics
PRLD
$361M
| $16.7M | 0.17% |
583,333
-43,169
| -7% | -$1.54M |
|
60
Snowflake
SNOW
$99.9B
| $15.2M | 0.16% |
63,000
| – | – |
|
|
SOHU
61
Sohu.com
SOHU
$348M
| $14.9M | 0.15% |
802,034
| – | – |
|
62
Kura Oncology
KURA
$787M
| $13.6M | 0.14% |
650,000
| – | – |
|
|
IGMS
63
DELISTED
IGM Biosciences
IGMS
| $12.6M | 0.13% |
151,390
| – | – |
|
|
TRML
64
DELISTED
Tourmaline Bio
TRML
| $12.5M | 0.13% |
+85,334
| New | +$13.1M |
|
65
ADC Therapeutics
ADCT
$139M
| $12.2M | 0.13% |
500,000
| – | – |
|
66
Immunocore
IMCR
$1.67B
| $10.8M | 0.11% |
277,754
-1,826
| -0.7% | -$70.5K |
|
|
RNAM
67
DELISTED
Avidity Biosciences
RNAM
| $10.5M | 0.11% |
425,000
| – | – |
|
|
KRON
68
DELISTED
Kronos Bio
KRON
| $10.4M | 0.11% |
433,436
-225,000
| -34% | -$5.7M |
|
69
UiPath
PATH
$6.54B
| $10.2M | 0.1% |
+150,000
| New | +$11M |
|
|
MREO
70
Mereo BioPharma
MREO
$49.8M
| $9.43M | 0.1% |
2,976,121
| – | – |
|
|
UXIN
71
Uxin Ltd
UXIN
$284M
| $8.85M | 0.09% |
22,973
| – | – |
|
72
Nkarta
NKTX
$152M
| $8.8M | 0.09% |
277,778
-81,750
| -23% | -$2.36M |
|
73
Cogent Biosciences
COGT
$6.67B
| $8.11M | 0.08% |
1,000,000
| – | – |
|
|
CDAK
74
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| $6.79M | 0.07% |
366,721
| – | – |
|
|
CYPH
75
Cypherpunk Technologies Inc
CYPH
$63.1M
| $5.86M | 0.06% |
357,575
| – | – |
|
Similar funds
TFS
GC
PA
LCI
JPM
NRI
CPO
JIP
HHLR Advisors's Q2 2021 Portfolio in Review
As of Q2 2021, HHLR Advisors held 100 positions worth $9.71B, down 4% from $10.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
HHLR Advisors withdrew a net $603M in Q2 2021, closing 11 positions and reducing 17 holdings. Its most notable exit was China Biologic Products Holdings, Inc., an estimated $351M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, HHLR Advisors opened a new position in Airbnb worth $324M.
- HHLR Advisors's largest Q2 2021 buy was Airbnb: 2,112,637 shares worth $324M.
- HHLR Advisors added most to Vipshop in Q2 2021, an estimated $213M increase.
- HHLR Advisors's biggest Q2 2021 reduction was Pinduoduo, cutting an estimated $432M.
- HHLR Advisors fully exited China Biologic Products Holdings, Inc. in Q2 2021, selling an estimated $351M.
- HHLR Advisors's ten largest holdings make up 61% of its $9.71B portfolio in Q2 2021.
- HHLR Advisors opened 9 new positions and closed 11 in Q2 2021.
- HHLR Advisors's portfolio value fell 4% quarter-over-quarter to $9.71B.
Based on HHLR Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.